Overview

This book provides an in-depth examination of carnitine, a crucial nutrient for mitochondrial function and energy metabolism. It explores the discovery, biochemical properties, and physiological roles of carnitine, offering a comprehensive understanding of its significance in human health. The chapters cover a wide range of topics, including the carnitine cycle, its transport mechanisms, and the biochemical pathways it influences. Readers will gain insights into the nutrient's newly discovered roles, such as its anti-inflammatory, antioxidant, and anti-apoptotic effects. The book also addresses the clinical implications of carnitine deficiency, exploring its impact on inherited metabolic diseases, kidney and liver disorders, and cardiovascular health. With detailed discussions on the safety and pharmacokinetics of carnitine, this volume provides a balanced perspective on its therapeutic potential. This book is an invaluable resource for medical professionals, researchers, and students in the fields of biochemistry, pharmacology, and clinical medicine. It offers a thorough exploration of carnitine's roles and applications, making it a must-read for those seeking to understand its impact on health and disease. By bridging the gap between basic science and clinical practice, this book equips readers with the knowledge needed to address the challenges of carnitine deficiency and harness its therapeutic benefits.

Full Product Details

9789819577965

Table of Contents

Reviews

Author Information

Dr. Natsuki Nakayama earned his Ph.D. in 1980 for his research on the biogenesis of plant mitochondria. He subsequently joined Otsuka Pharmaceutical, where he conducted research in cardiovascular and diabetes pharmacology before moving into clinical drug development for cardiovascular therapeutics. In 2007, Dr. Nakayama began work on a specialized carnitine project. At that time, pharmaceutical-grade carnitine in Japan was approved solely for carnitine deficiency associated with methylmalonic acidemia and propionic acidemia. In 2011, he successfully broadened its indication to general “carnitine deficiency” without the need for clinical trials. He was further involved in the development of intravenous and oral liquid formulations, as well as in vitro diagnostic tools for identifying carnitine deficiency. Because the term “carnitine deficiency” entered the Japanese medical community rather abruptly, many physicians and medical staff were initially unfamiliar with the condition. To address this gap, Dr. Nakayama delivered hundreds of lectures across Japan, explaining the physiological role of carnitine and the clinical significance of carnitine supplementation in deficiency states. Through these extensive educational and outreach efforts, he has come to be recognized as a rare and distinctive expert in the science and clinical application of carnitine.

Tab Content 6

Countries Available